TXMD

SEC source: 0001387131-20-003592 · finizio-form4_033020.xml · derivative · entry 1

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 475,000

Underlying: Common Stock · 475,000 shares

Expires not disclosed

F1 · shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.exercise_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.expiration_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.underlying_shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · balance_after: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001387131-20-003591 · krassan-form4_033020.xml · derivative · entry 2

Krassan Mitchell · CIK 0001532232 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,500

Underlying: Common Stock · 151,500 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

SEC source: 0001387131-20-003591 · krassan-form4_033020.xml · derivative · entry 1

Krassan Mitchell · CIK 0001532232 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,500

Underlying: Common Stock · 151,500 shares

Expires not disclosed

F1 · shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.exercise_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.expiration_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.underlying_shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · balance_after: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001387131-20-003590 · cartwright-form4_033020.xml · derivative · entry 2

Cartwright Daniel A · CIK 0001532231 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,500

Underlying: Common Stock · 151,500 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

SEC source: 0001387131-20-003590 · cartwright-form4_033020.xml · derivative · entry 1

Cartwright Daniel A · CIK 0001532231 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,500

Underlying: Common Stock · 151,500 shares

Expires not disclosed

F1 · shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.exercise_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.expiration_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.underlying_shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · balance_after: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001387131-20-003589 · donegan-form4_033020.xml · derivative · entry 2

Donegan Michael C · CIK 0001627810 · Vice President Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,000

Underlying: Common Stock · 57,000 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

SEC source: 0001387131-20-003589 · donegan-form4_033020.xml · derivative · entry 1

Donegan Michael C · CIK 0001627810 · Vice President Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,000

Underlying: Common Stock · 57,000 shares

Expires not disclosed

F1 · shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.exercise_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.expiration_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · derivative.underlying_shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F1 · balance_after: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001387131-21-003349 · finizio-form4_030421.xml · nonDerivative · entry 4

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,901,000

SEC source: 0001387131-20-001050 · krassan-form4_020320.xml · derivative · entry 5

Krassan Mitchell · CIK 0001532232 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 489,658

Underlying: Common Stock · 194,297 shares

Expires 2020-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-20-001050 · krassan-form4_020320.xml · derivative · entry 4

Krassan Mitchell · CIK 0001532232 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 105,703 shares

Expires 2020-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-20-001050 · krassan-form4_020320.xml · nonDerivative · entry 3

Krassan Mitchell · CIK 0001532232 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan dated December 10, 2019 with respect to shares of common stock underlying options to purchase common stock that expire on or before September 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.285, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-20-001050 · krassan-form4_020320.xml · nonDerivative · entry 2

Krassan Mitchell · CIK 0001532232 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-20-001050 · krassan-form4_020320.xml · nonDerivative · entry 1

Krassan Mitchell · CIK 0001532232 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-19-007990 · milligan-form4_102519.xml · nonDerivative · entry 1

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,544,419

F1 · shares: Represents a purchase from the underwriters in the issuer's public offering.

SEC source: 0001387131-19-007992 · milligan-form4_102519.xml · nonDerivative · entry 1

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,544,419

F1 · shares: Represents a purchase from the underwriters in the issuer's public offering.

SEC source: 0001387131-19-007989 · bernick-form4_102519.xml · nonDerivative · entry 1

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,000

F1 · shares: Represents a purchase from the underwriters in the issuer's public offering.

SEC source: 0001387131-19-007988 · finizio-form4_102519.xml · nonDerivative · entry 1

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,325,964

F1 · shares: Represents a purchase from the underwriters in the issuer's public offering.

SEC source: 0001387131-19-006606 · ownership.xml · derivative · entry 1

Krassan Mitchell · CIK 0001532232 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2029-08-28

F1 · derivative.exercise_date: Underlying shares vest as follows: 100,000 shares on the first anniversary date of the grant, 100,000 shares on the second anniversary date of the grant, and 100,000 shares on the third anniversary date of the grant.

SEC source: 0001387131-19-006604 · ownership.xml · derivative · entry 1

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2029-08-28

F1 · derivative.exercise_date: Underlying shares vest as follows: 100,000 shares on the first anniversary date of the grant, 100,000 shares on the second anniversary date of the grant, and 100,000 shares on the third anniversary date of the grant.

SEC source: 0001387131-19-006607 · ownership.xml · derivative · entry 1

Donegan Michael C · CIK 0001627810 · Vice President Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2029-08-28

F1 · derivative.exercise_date: Underlying shares vest as follows: 40,000 shares on the first anniversary date of the grant, 40,000 shares on the second anniversary date of the grant, and 40,000 shares on the third anniversary date of the grant.

SEC source: 0001387131-19-006605 · ownership.xml · derivative · entry 1

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2029-08-28

F1 · derivative.exercise_date: Underlying shares vest as follows: 133,334 shares on the first anniversary date of the grant, 133,333 shares on the second anniversary date of the grant, and 133,333 shares on the third anniversary date of the grant.

SEC source: 0001387131-19-006603 · ownership.xml · derivative · entry 1

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

Underlying: Common Stock · 1 shares

Expires 2029-08-28

SEC source: 0001387131-19-006602 · ownership.xml · derivative · entry 1

Cartwright Daniel A · CIK 0001532231 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 220,000 shares

Expires 2029-08-28

F1 · derivative.exercise_date: Underlying shares vest as follows: 73,334 shares on the first anniversary date of the grant, 73,333 shares on the second anniversary date of the grant, and 73,333 shares on the third anniversary date of the grant.

SEC source: 0001387131-19-006399 · ownership.xml · nonDerivative · entry 1

Russell Angus C. · CIK 0001534002 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.75 to $2.78, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4.

SEC source: 0001387131-19-006289 · ownership.xml · nonDerivative · entry 1

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,253,964

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.70 to $2.79 inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (1) to this Form 4.

SEC source: 0001387131-19-006246 · ownership.xml · nonDerivative · entry 1

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,582,373

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.87 to $2.99, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4.

F2 · ownership.nature: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended.

SEC source: 0001387131-19-006191 · ownership.xml · nonDerivative · entry 2

Russell Angus C. · CIK 0001534002 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,500

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.98 to $3.00, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (2) to this Form 4.

SEC source: 0001387131-19-006191 · ownership.xml · nonDerivative · entry 1

Russell Angus C. · CIK 0001534002 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.73 to $2.77, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4.

SEC source: 0001387131-19-006151 · ownership.xml · nonDerivative · entry 1

Barlow Jane F · CIK 0001736026 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,144

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.17 to 3.18, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4.

SEC source: 0001387131-19-006150 · ownership.xml · nonDerivative · entry 1

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,572,373

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to 3.19, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4.

F2 · ownership.nature: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended.

SEC source: 0001387131-19-006018 · finizio-form4_022819.xml · nonDerivative · entry 2

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,218,964

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $3.00, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (1) to this Form 4.

SEC source: 0001387131-19-006036 · thompson-form4_080919.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 690,900

F1 · ownership.nature: The reported securities are owned by Thompson Family Investments, LLC, an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr. Thompson.

SEC source: 0001387131-19-006033 · bernick-form4_080919.xml · nonDerivative · entry 1

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.89, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4.

SEC source: 0001387131-19-004590 · thompson-form4_062019.xml · derivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2029-06-20

SEC source: 0001387131-19-004589 · segal-form4_062019.xml · derivative · entry 1

SEGAL NICHOLAS · CIK 0001543494 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-06-20

SEC source: 0001387131-19-004588 · russell-form4_062019.xml · derivative · entry 1

Russell Angus C. · CIK 0001534002 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-06-20

SEC source: 0001387131-19-004585 · collins-form4_062019.xml · derivative · entry 1

Collins Cooper C. · CIK 0001485508 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-06-20

SEC source: 0001387131-19-004587 · musing-form4_062019.xml · derivative · entry 1

MUSING JULES A. · CIK 0001524216 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-06-20

SEC source: 0001387131-19-004586 · lapenta-form4_062019.xml · derivative · entry 1

LaPenta Robert V Jr · CIK 0001543405 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-06-20

SEC source: 0001387131-19-004584 · carroll-form4_062019.xml · derivative · entry 1

CARROLL J MARTIN · CIK 0001279901 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-06-20

SEC source: 0001387131-19-004583 · barlow-form4_062019.xml · derivative · entry 1

Barlow Jane F · CIK 0001736026 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-06-20

SEC source: 0001387131-19-003606 · thompson-form4_051319.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 685,900

F1 · ownership.nature: Owned by Thompson Family Investments, LLC an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr. Thompson.

SEC source: 0001387131-19-003731 · collins-form4_051319.xml · nonDerivative · entry 1

Collins Cooper C. · CIK 0001485508 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.33, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001387131-19-006018 · finizio-form4_022819.xml · nonDerivative · entry 1

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,166,559

SEC source: 0001387131-19-001657 · musing-form4_022719.xml · nonDerivative · entry 1

MUSING JULES A. · CIK 0001524216 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001387131-18-006984 · finizio-form4_121918.xml · derivative · entry 8

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 92,910 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006984 · finizio-form4_121918.xml · nonDerivative · entry 4

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,366,559

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.845, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-006984 · finizio-form4_121918.xml · nonDerivative · entry 3

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,459,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006984 · finizio-form4_121918.xml · derivative · entry 7

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,910

Underlying: Common Stock · 92,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006984 · finizio-form4_121918.xml · nonDerivative · entry 2

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,366,559

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.875, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.